Raziel/Fosun的RZL-012中国三期达标，GC Wellbeing韩国权益获临床去风险

Raziel Therapeutics, a partner of GC Wellbeing, met the main endpoints in a late-stage trial in China of its next-generation fat-dissolving drug, a result analysts said improves commercialization prospects for GC Wellbeing, which holds the Korean license.
Raziel Therapeutics said on the 3rd that it had obtained topline data showing its next-generation fat-dissolving injection RZL-012 met the main efficacy and safety endpoints in a Phase 3 trial in China. GC Wellbeing holds the exclusive Korean license to RZL-012 and has also made a strategic equity investment in Raziel.
The Phase 3 study was a pivotal registration trial conducted by Zhuvstar, an affiliate of Chinese partner Fosun Pharma, in 480 adult patients with submental fat, or a double chin.
RZL-012 met both the primary and secondary efficacy endpoints at day 84 after a single treatment cycle, the company said. In the primary efficacy assessment, the drug showed a response-rate gap of more than 30 percentage points against placebo, confirming a statistically significant reduction in fat. Safety results were also favorable.
RZL-012 is a next-generation localized fat-reduction candidate that works by irreversibly destroying targeted fat cells. It is being developed to reduce fat in a localized area with only one or two injections, fewer than existing fat-dissolving procedures.
Based on the results, Fosun Pharma and Raziel plan to file a new drug application with China's National Medical Products Administration. They also plan additional trials to expand the indication beyond the double chin to body-contouring areas such as the abdomen and thighs.
GC Wellbeing (234690.KQ), which holds the Korean license, aims to develop RZL-012 as a body-contouring treatment that can be used before, after or alongside weight-loss therapy based on glucagon-like peptide-1 (GLP-1) obesity drugs.
"These Phase 3 results allowed us to confirm the commercialization potential of RZL-012," an official at GC Wellbeing said. "As demand for body contouring grows along with the obesity treatment market, we will build a differentiated portfolio centered on RZL-012 that connects obesity care with medical aesthetics."